Dr. Mark Emberton on the Role of Focal Therapy in Prostate Cancer
Emberton says that in treatment of most solid tumor cancers, oncologists have moved from treating the whole organ to specifically targeting the tumor.
Mark Emberton, MD, FRCS, professor of surgery, University College, London, discusses the role of focal therapy in prostate cancer. Emberton says that in treatment of most solid tumor cancers, oncologists have moved from treating the whole organ to specifically targeting the tumor. He adds that the prostate is one of the last organs where treatment is mainly focused on the whole organ, rather than the tumor itself.
Emberton says that treatment of the whole prostate is not an ideal form of therapy, and that with modern imaging and treatments, oncologists should be able to specifically attack the tumor. Treatment options include freezing the tumor and removing it, as well as heating it to a degree at which it would no longer be able to function.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
